MenABCWY

MenABCWY vaccine is currently in preclinical development. The vaccine will combine glycoconjugate antigens (A, C, W and Y) and Neisseria meningitidis group B recombinant proteins with different adjuvants and/or delivery systems.

decrease text sizeincrease text size contact help

About Novartis

About Novartis

We provide medicines to treat and prevent diseases, ease suffering and improve quality of life.

Learn more about our company

News

20 June 2008
Dr. Joerg Reinhardt, CEO of Novartis Vaccines and Diagnostics, and Hesse’s Secretary for Economic Affairs, Dr. Alois Rhiel, broke ground together with other representatives of industry and politics today for a €145 million investment project. This symbolic act launched the building operations for the Novartis MARS project.

04 June 2008
Late stage development pipeline with Menveo and MenB vaccines creating meningococcal vaccine franchise with strong growth potential. Novartis leverages research excellence with first in class vaccines in early pipeline, preventing infections from Helicobacter pylori, Group B Streptococcus and other pathogens which pose significant public health challenges.

>>rong portfolio of meningitis vaccines.

>>

 

 

oter.inc" -->